Viracta Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch VIRX and buy or sell other stocks, ETFs, and their options commission-free!About VIRX
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas.
CEOMark A. Rothera, MBA
CEOMark A. Rothera, MBA
Employees—
Employees—
HeadquartersCardiff, California
HeadquartersCardiff, California
Founded1998
Founded1998
Employees—
Employees—
VIRX Key Statistics
Market cap389.49K
Market cap389.49K
Price-Earnings ratio-0.01
Price-Earnings ratio-0.01
Dividend yield—
Dividend yield—
Average volume491.85K
Average volume491.85K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.58
52 Week high$0.58
52 Week low$0.008
52 Week low$0.008
Stock Snapshot
With a market cap of 389.49K, Viracta Therapeutics(VIRX) trades at $0.01. The stock has a price-to-earnings ratio of -0.01.
On 2025-12-27, Viracta Therapeutics(VIRX) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for Viracta Therapeutics(VIRX) stock has reached 0, versus its average volume of 491.85K.
The stock's 52-week range extends from a low of $0.01 to a high of $0.58.
The stock's 52-week range extends from a low of $0.01 to a high of $0.58.
People also own
Based on the portfolios of people who own VIRX. This list is generated using Robinhood data, and it’s not a recommendation.